Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. AIDS researchers have many reasons to be encouraged. Studies show that treatments combining new and old drugs can control HIV levels in the blood. Moreover, many scientists and activists note, prevention efforts have helped reduce HIV infection rates. Yet the enthusiasm is tempered by several caveats. Drugs are expensive and have harsh side effects, leading
Discoveries announced at conference leave scientists feeling optimistic; yet their enthusiasm is tempered by several persistent concerns. |
Still, optimism is running high about recent advances in AIDS research, news of which was the highlight of the 11th International Conference ...
In mammals, intracellular clocks begin to tick within days of fertilization.
View this Issue
Learn how mastering the ins and outs of PCR can accelerate workflows and improve data.
Polypharmacology allows scientists to explore novel therapeutic purposes for existing drugs and opens new doors to treat multifactorial diseases.
Molecular detection technologies help scientists rapidly and reliably find and address ever-evolving pathogens with optimal accuracy and sensitivity.
Discover the key features to consider when selecting a new refrigerator or freezer
On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).
Slow temperature recovery can threaten the integrity of your work. That’s Stirling Ultracold designed the VAULT100™ to operate at setpoints down to -100°C, so your samples may never be exposed to temperatures above -70°C during a typical door opening.
The next generation imager from the ChemiDoc Imaging System line. Effortlessly capture gel and western blot images from your benchtop without compromising on sensitivity and precision.
• Ongoing strategic partnership advances joint pipeline in neurodegeneration research
• Evotec receives a $20 million payment to further progress research
